The presentation of SARS-CoV-2 peptides by the common HLA-A
immunology
structural biology
virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
19 Feb 2021
19 Feb 2021
Historique:
received:
19
10
2020
revised:
17
12
2020
accepted:
15
01
2021
pubmed:
2
2
2021
medline:
2
2
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
CD8+ T cells are crucial for anti-viral immunity; however, understanding T cell responses requires the identification of epitopes presented by human leukocyte antigens (HLA). To date, few SARS-CoV-2-specific CD8+ T cell epitopes have been described. Internal viral proteins are typically more conserved than surface proteins and are often the target of CD8+ T cells. Therefore, we have characterized eight peptides derived from the internal SARS-CoV-2 nucleocapsid protein predicted to bind HLA-A
Identifiants
pubmed: 33521593
doi: 10.1016/j.isci.2021.102096
pii: S2589-0042(21)00064-X
pmc: PMC7825995
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102096Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
J Exp Med. 1992 Apr 1;175(4):1143-5
pubmed: 1552285
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4440-5
pubmed: 27036003
N Engl J Med. 1983 Jul 7;309(1):13-7
pubmed: 6602294
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Nat Immunol. 2019 May;20(5):613-625
pubmed: 30778243
J Immunol. 1981 Mar;126(3):1036-41
pubmed: 6970211
Nat Immunol. 2008 Nov;9(11):1236-43
pubmed: 18836451
J Biol Chem. 2015 Jan 30;290(5):2593-603
pubmed: 25505266
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Nat Commun. 2018 Dec 21;9(1):5427
pubmed: 30575715
Immunity. 2008 May;28(5):710-22
pubmed: 18468462
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Mol Cell. 1998 Mar;1(4):531-41
pubmed: 9660937
Nat Chem Biol. 2018 Oct;14(10):934-942
pubmed: 30224695
Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5534-9
pubmed: 20212169
Cancer Immunol Res. 2019 Jan;7(1):50-61
pubmed: 30425106
Nat Commun. 2019 Dec 6;10(1):5579
pubmed: 31811120
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Eur J Immunol. 2012 Jun;42(6):1405-16
pubmed: 22678897
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Immunogenetics. 1999 Nov;50(3-4):201-12
pubmed: 10602880
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24384-24391
pubmed: 32913053
Immunol Cell Biol. 2011 Mar;89(3):340-5
pubmed: 21301482
J Immunol. 2000 Jun 15;164(12):6398-405
pubmed: 10843695
J Virol. 2008 Jun;82(11):5161-6
pubmed: 18353950
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
Nat Rev Immunol. 2020 Sep;20(9):519
pubmed: 32686754
Immunol Cell Biol. 2013 Feb;91(2):184-94
pubmed: 23399741
J Infect Dis. 2015 Jul 1;212(1):81-5
pubmed: 25583167
Antiviral Res. 2014 Mar;103:39-50
pubmed: 24418573
PLoS Pathog. 2010 Aug 12;6(8):e1001039
pubmed: 20711359
Biochem Biophys Res Commun. 2006 May 26;344(1):63-71
pubmed: 16630549
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
PLoS Med. 2006 Oct;3(10):e403
pubmed: 17076553
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
Vaccine. 2007 Aug 10;25(32):6070-7
pubmed: 17629360
J Hosp Infect. 2002 May;51(1):59-64
pubmed: 12009822
J Virol. 2014 Feb;88(3):1684-93
pubmed: 24257602